ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

VSTM Verastem Inc

9.38
0.00 (0.00%)
시간외 단일가
최종 업데이트: 17:09:53
15분 지연
기업명 주식 심볼 시장 주식 타입
Verastem Inc VSTM 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.00 0.00% 9.38 17:09:53
개장가 저가 고가 종가 전일 종가
9.38
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
19/04/202405:05BWVerastem Oncology Announces Appointment of John Hayslip,..
04/04/202420:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
18/03/202420:00BWGlobal Patient Survey Results Reveal Significant Negative..
15/03/202405:05BWVerastem Oncology Reports Fourth Quarter and Full Year 2023..
12/03/202406:07EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/03/202420:30BWVerastem Oncology Announces Multiple Oral Presentations at..
06/03/202407:27BWVerastem Oncology Receives Orphan Drug Designation from FDA..
06/03/202406:30BWVerastem Oncology Announces Preclinical Presentations for..
09/02/202406:22EDGAR2Form SC TO-I - Tender offer statement by Issuer
02/02/202423:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/01/202406:01EDGAR2Form 8-K - Current report
29/01/202421:00BWVerastem Oncology Outlines Key 2024 Strategic Priorities and..
19/01/202421:54EDGAR2Form 8-K - Current report
19/01/202406:00BWVerastem Oncology Granted Fast Track Designation for..
11/01/202421:00BWVerastem Oncology to Participate in the B. Riley Securities..
10/01/202406:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/01/202406:02EDGAR2Form 8-K - Current report
05/01/202421:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
29/12/202306:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202306:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202306:01EDGAR2Form DEF 14A - Other definitive proxy statements
18/12/202321:00BWVerastem Oncology Selects Oral KRAS G12D Inhibitor..
13/12/202321:00BWVerastem Oncology Announces Initiation of a Confirmatory..
09/12/202306:10EDGAR2Form PRE 14A - Other preliminary proxy statements
21/11/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202321:00BWNew Healthcare Professional Component of Let’s Talk About..
09/11/202307:01EDGAR2Form S-3 - Registration statement under Securities Act of..
09/11/202306:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:12BWVerastem Oncology Reports Third Quarter 2023 Financial..
07/11/202321:00BWFirst-Of-Its-Kind, Multi-National Patient Impact Survey..
06/11/202321:00BWVerastem Oncology Announces Efficacy and Safety Data of..
28/10/202305:41EDGAR2Form 8-K - Current report
27/10/202305:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/10/202305:05BWVerastem Oncology Strengthens Executive Leadership Team with..
19/10/202305:50BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
15/10/202301:30BWVerastem Oncology Announces Initial Results of RAMP 203..
11/10/202305:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202320:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
29/09/202303:27EDGAR2Form 8-K - Current report
29/09/202303:15BWVerastem Presents Avutometinib and Defactinib Combination..
26/09/202305:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/09/202305:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/09/202305:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/09/202305:08EDGAR2Form 8-K - Current report
05/09/202320:00BWVerastem Oncology to Participate in Upcoming Investor..
28/08/202320:00BWVerastem Oncology Enters Discovery and Development..
09/08/202305:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/08/202305:05BWVerastem Oncology Reports Second Quarter 2023 Financial..

최근 히스토리

Delayed Upgrade Clock